[Studies on antinephritic effects of plant components in rats (1). Effects of saikosaponins original-type anti-GBM nephritis in rats and its mechanisms].
This study was designed to clarify the anti-nephritic effects of the saikosaponins that are contained in Bupleurum falcatum L. crude saikosaponin at 1.0 mg and 5.0 mg/kg, i.p. prevented urinary protein excretion and elevation of serum cholesterol content on the 10th day after the injection of anti-GBM serum. Moreover, crude saikosaponin at 1.0 mg and 5.0 mg/kg, i.p. significantly inhibited histopathological changes such as hypercellularity and adhesion. On the other hand, saikosaponin a (5.0 mg/kg, i.p.) and d (1.0 mg and 5.0 mg/kg, i.p.) also prevented urinary protein excretion, elevation of serum cholesterol content, and histopathological changes. In the second study, to clarify the anti-nephritic mechanisms of saikosaponins on this model, we investigated the effect of saikosaponins on platelet aggregation, release of corticosterone and reactive oxygen species scavengers activity. Crude saikosaponin and saikosaponin d significantly inhibited the increase in platelet aggregation, and saikosaponin d enhanced the serum and intra-adrenal corticosterone levels. Crude saikosaponin and saikosaponin a inhibited the decrease in activity of scavengers (SOD, catalase, glutathione peroxidase). These results indicate that saikosaponins were effective on this model, and anti-nephritic mechanisms of saikosaponins were party due to anti-platelet, corticosterone releasing and enhancing action on the activity of reactive oxygen species scavengers.
Hattori
T
T
Department of Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Ito
M
M
Suzuki
Y
Y
D000818:Animals; D002784:Cholesterol / Q000097:blood; D003345:Corticosterone / Q000097:blood; D016166:Free Radical Scavengers; D005921:Glomerulonephritis / Q000188:drug therapy*; D005979:Glutathione Peroxidase / Q000378:metabolism; D007668:Kidney / Q000201:enzymology; D008297:Male; D009828:Oleanolic Acid / Q000031:analogs & derivatives*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011507:Proteinuria; D051381:Rats; D011919:Rats, Inbred Strains; D012502:Sapogenins / Q000494:pharmacology / Q000627:therapeutic use*; D012503:Saponins; D013482:Superoxide Dismutase / Q000378:metabolism
D016166:Free Radical Scavengers; D010975:Platelet Aggregation Inhibitors; D012502:Sapogenins; D012503:Saponins; D009828:Oleanolic Acid; D002784:Cholesterol; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; C025759:saikosaponin D; D003345:Corticosterone